Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.

Paul W. Sperduto,Shane Mesko,Jing Li,Daniel N. Cagney,Ayal A. Aizer,Nan Lin,Eric Nesbit,Tim J. Kruser,Jason Chan,Steve Braunstein,J. Lee,John P. Kirkpatrick,Will Breen,Paul D. Brown,Diana D. Shi,Helen A. Shih,Hany Soliman,Arjun Sahgal,Ryan Shanley,William Sperduto,Emil Lou,Ashlyn S. Everett,Drexell Hunter Boggs,Laura Masucci,David Roberge,Jill Remick,Kristin Plichta,John M. Buatti,Supriya K. Jain,Laurie E. Gaspar,Cheng-Chia Wu,Tony J. C. Wang,John Bryant,Michael D. Chuong,Yi An,Veronica L. Chiang,Toshimichi Nakano,Hidefumi Aoyama,Minesh P. Mehta

Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.

2020

PURPOSEConventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group...

Keywords:

in patient
Quotient
Clinical trial
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations